Atea Pharmaceuticals Inc. (AVIR) News
Filter AVIR News Items
AVIR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AVIR News Highlights
- AVIR's 30 day story count now stands at 6.
- Over the past 21 days, the trend for AVIR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about AVIR are DRUG.
Latest AVIR News From Around the Web
Below are the latest news stories about ATEA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AVIR as an investment opportunity.
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral ResearchLow risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies Bemnifosbuvir retains activity against all SARS-CoV-2 variants of concern evaluated as well as other human coronaviruses such as HCoV-229E, HCoV-OC43, and SARS-CoV-1 Favorable absorption, distribution, metabolism, and excretion profile demonstrated for bemnifosbuvir Synergistic antiviral effect observed for the combination of bemnifosbuvir and ruzasvir against HCV in vitro B |
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral ResearchBOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for several viral diseases, today announced six upcoming presentations at the 36th International Conference on Antiviral Research (ICAR), which will take place March 13-17, 2023 in Lyon, France. Presentation details are as follows: Poster Number: 411Title: The Combination of Bemnifosbu |
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2022 Earnings Call TranscriptAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals’ Fourth Quarter and Full Year 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call […] |
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatePhase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; interim analysis expected in 2H23 Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV to start enrollment in 2Q23; initial results expected by 4Q23 AT-752 dengue program results and update Conference call at 4:30 pm ET today BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharma |
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions BOSTON, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that data from three Phase 1 studies suggest a favorable drug-drug interaction profile. No dosage adjustment is needed for CYP3A substrates or for drugs that are sensitive substrates of efflux and hepatic uptake transporters when co-administ |
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, February 28, 2023, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022, and to provide a business update. To access the live conference call, participants may register here. While not required, it is recommended that parti |
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic InfectionsBOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), which will take place February 19-22, 2023 in Seattle, Washington. Details for the poster presentations are as follows: Poster Number: 512 Title: No Dose Adjustments for CYP3A4 Substrates When Co-Administered with BemnifosbuvirSession: Pharm |
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is a favorite amongst institutional investors who own 62%Every investor in Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) should be aware of the most powerful shareholder groups... |
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma ConferenceBOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 3:00 p.m. ET. A live webcast of the presentation will be avai |
Atea Pharmaceuticals Highlights Strategic Priorities for 2023Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept Results for AT-752 for Dengue Expected 1Q23 Enrollment Expected to Initiate 2Q23 for Phase 2 Combination Trial of Bemnifosbuvir and Ruzasvir in Patients Infected with Hepatitis C Virus (HCV) with Initial Results Anticipated 4Q23 BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: |